AI CuratorAI-generated
Research summary · AI summary · not yet reviewedHuman studyNot reportedPublished in a peer-reviewed journal
Familact and Probiotic Effects on Fatigue in MS Patients
In a study involving 54 MS patients, those who received Familact, a combination of multistrain probiotics and a prebiotic, showed significant improvements in fatigue levels compared to those taking a placebo, evaluated over a 30-day period.
- Tags
- #MSResearch
- Most relevant to
- —
This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
- Human efficacy
- Not established from this source
- Mechanism
- Not reported
- Evidence strength
- Not graded
- Outcome
- Not reported
Why it matters
This finding is significant as it suggests that probiotics may help reduce fatigue, a common and debilitating symptom in MS patients, potentially improving their quality of life.
What this does not prove
However, the findings do not confirm causation and further research is needed to validate these results and understand the mechanisms involved.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- 54 · Participants allocated to receive Familact or placebo
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-09-29
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- Not reported
- Pathway
- Not reported
- Population
- MS patients
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- Not reported
- Safety
- no reported adverse reactions
Original sources
- Primary evidenceThe Role of Synbiotics in Alleviating Fatigue Among Multiple Sclerosis Patients: A Randomized Controlled Trial. ↗DOI: 10.4103/ijpvm.ijpvm_130_25
Supporting passages (13)
sample size54
sample size basisMETHODS: A double-blind, randomized controlled trial was conducted with 54 MS patients allocated to receive either Familact or a placebo for 30 days.
publication date2026-09-29
interventionFamilact, Multistrains probiotics, and a prebiotic
comparatorplacebo
primary endpointFatigue levels were assessed using the Fatigue Severity Scale at baseline and after the intervention.
follow up30 days
findingsPatients receiving Familact showed significant improvements in fatigue levels compared to the placebo group
limitationsFurther large-scale, long-term studies are warranted to confirm these findings and explore underlying mechanisms.
populationMS patients
safety signalsno reported adverse reactions
peer reviewedPublication types: Journal Article
subjectsTitle: The Role of Synbiotics in Alleviating Fatigue Among Multiple Sclerosis Patients: A Randomized Controlled Trial.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.